On September 13, India’s Union Health Ministry added 34 drugs to the National List of Essential Medicines (NLEM) and dropped 26 drugs. Newer and better anti-infectives, anti-nicotine replacements, treatments for diabetics, tuberculosis, etc. were added. Older and less effective gastrointestinal drugs and disinfectant products were dropped. The NLEM prices are determined by the National Pharmaceutical Pricing Authority (NPPA). The NPPA currently regulates the prices of 384 drugs which cover about 1,000 formulations. 42 cancer drugs are on India’s NLEM list, but many new, high-priced anti-cancer drugs are not.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.